Gilead Announces Sustained Virologic Response Rate Of 78% From Phase 3 Study Of Sofosbuvir For Genotype 2/3 Hepatitis C Infected Patients
Gilead Sciences (Nasdaq:GILD) today announced topline results from the
Phase 3 POSITRON study examining a 12-week course of once-daily
sofosbuvir plus ribavirin (RBV) in patients with genotype 2 or 3 chronic
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.